| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| September 25th, 2009 | 40 | No |
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 6.06 | 6.22 | -9.92 | 5 | 10 | 0 | 155 | 578.784 | 26 | ↓ |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| AKT1-1-E | RAC-alpha Serine/threonine-protein Kinase (cluster #1 Of 3), Eukaryotic | Eukaryotes | 5000 | 0.19 | Binding ≤ 10μM |
| AKT1-1-E | RAC-alpha Serine/threonine-protein Kinase (cluster #1 Of 3), Eukaryotic | Eukaryotes | 5000 | 0.19 | Binding ≤ 10μM |
| AKT2-1-E | Serine/threonine-protein Kinase AKT2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.19 | Binding ≤ 10μM |
| AKT2-1-E | Serine/threonine-protein Kinase AKT2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.19 | Binding ≤ 10μM |
| AKT3-1-E | Serine/threonine-protein Kinase AKT3 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.19 | Binding ≤ 10μM |
| AKT3-1-E | Serine/threonine-protein Kinase AKT3 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.19 | Binding ≤ 10μM |
| Z80166-2-O | HT-29 (Colon Adenocarcinoma Cells) (cluster #2 Of 12), Other | Other | 10000 | 0.18 | Functional ≤ 10μM |
| Z80166-2-O | HT-29 (Colon Adenocarcinoma Cells) (cluster #2 Of 12), Other | Other | 10000 | 0.18 | Functional ≤ 10μM |
| Z80224-7-O | MCF7 (Breast Carcinoma Cells) (cluster #7 Of 14), Other | Other | 1200 | 0.21 | Functional ≤ 10μM |
| Z80224-7-O | MCF7 (Breast Carcinoma Cells) (cluster #7 Of 14), Other | Other | 1250 | 0.21 | Functional ≤ 10μM |
| Z80390-2-O | PC-3 (Prostate Carcinoma Cells) (cluster #2 Of 10), Other | Other | 2000 | 0.20 | Functional ≤ 10μM |
| Z80390-2-O | PC-3 (Prostate Carcinoma Cells) (cluster #2 Of 10), Other | Other | 10000 | 0.18 | Functional ≤ 10μM |
| Z80951-4-O | NIH3T3 (Fibroblasts) (cluster #4 Of 4), Other | Other | 2000 | 0.20 | Functional ≤ 10μM |
| Z81247-3-O | HeLa (Cervical Adenocarcinoma Cells) (cluster #3 Of 9), Other | Other | 2500 | 0.20 | Functional ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| AKT1_HUMAN | P31749 | Serine/threonine-protein Kinase AKT, Human | 5000 | 0.19 | Binding ≤ 10μM |
| AKT2_HUMAN | P31751 | Serine/threonine-protein Kinase AKT2, Human | 5000 | 0.19 | Binding ≤ 10μM |
| AKT3_HUMAN | Q9Y243 | Serine/threonine-protein Kinase AKT3, Human | 5000 | 0.19 | Binding ≤ 10μM |
| Z81247 | Z81247 | HeLa (Cervical Adenocarcinoma Cells) | 2500 | 0.20 | Functional ≤ 10μM |
| Z80166 | Z80166 | HT-29 (Colon Adenocarcinoma Cells) | 10000 | 0.18 | Functional ≤ 10μM |
| Z80224 | Z80224 | MCF7 (Breast Carcinoma Cells) | 1200 | 0.21 | Functional ≤ 10μM |
| Z80951 | Z80951 | NIH3T3 (Fibroblasts) | 2000 | 0.20 | Functional ≤ 10μM |
| Z80390 | Z80390 | PC-3 (Prostate Carcinoma Cells) | 2000 | 0.20 | Functional ≤ 10μM |
| Description | Species |
|---|---|
| Activation of BAD and translocation to mitochondria | |
| Activation of PKB | |
| AKT phosphorylates targets in the cytosol | |
| AKT phosphorylates targets in the nucleus | |
| AKT-mediated inactivation of FOXO1A | |
| Butyrate Response Factor 1 (BRF1) destabilizes mRNA | |
| CD28 dependent PI3K/Akt signaling | |
| Constitutive PI3K/AKT Signaling in Cancer | |
| CTLA4 inhibitory signaling | |
| deactivation of the beta-catenin transactivating complex | |
| Downregulation of ERBB2:ERBB3 signaling | |
| eNOS activation | |
| G beta:gamma signalling through PI3Kgamma | |
| GPVI-mediated activation cascade | |
| Inhibition of TSC complex formation by PKB | |
| Integrin alphaIIb beta3 signaling | |
| KSRP destabilizes mRNA | |
| Negative regulation of the PI3K/AKT network | |
| PDE3B signalling | |
| PIP3 activates AKT signaling | |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |
| Translocation of GLUT4 to the plasma membrane | |
| VEGFR2 mediated vascular permeability |
